Eli Lilly reported early Phase 1 clinical data for VERV-102, a gene-editing therapy acquired from Verve Therapeutics, showing a dose-dependent reduction in cholesterol. In the company’s update, high-dose participants saw LDL (“bad” cholesterol) drop by 62%, an early sign that a one-time intervention could reduce reliance on lifelong lipid-lowering regimens. Lilly said no treatment-related serious adverse events occurred in the Phase 1 study, an important point given Verve’s earlier program pauses linked to safety concerns. The company positioned the approach as a potential way to broadly prevent heart disease, where maintaining LDL control can be difficult for many patients on standard therapies. The readout is still preliminary and reflects early human dosing and tolerability, but it adds to the competitive momentum in in-vivo gene editing aimed at cardiometabolic risk reduction.